JP2012510302A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012510302A5 JP2012510302A5 JP2011534906A JP2011534906A JP2012510302A5 JP 2012510302 A5 JP2012510302 A5 JP 2012510302A5 JP 2011534906 A JP2011534906 A JP 2011534906A JP 2011534906 A JP2011534906 A JP 2011534906A JP 2012510302 A5 JP2012510302 A5 JP 2012510302A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- bladder
- scaffold
- tissue
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 471
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 341
- 210000001519 tissue Anatomy 0.000 claims description 250
- 238000000034 method Methods 0.000 claims description 223
- 239000011159 matrix material Substances 0.000 claims description 211
- 210000000056 organ Anatomy 0.000 claims description 164
- 229920000642 polymer Polymers 0.000 claims description 159
- 238000002054 transplantation Methods 0.000 claims description 114
- 210000000626 ureter Anatomy 0.000 claims description 110
- 230000014509 gene expression Effects 0.000 claims description 102
- 210000002700 urine Anatomy 0.000 claims description 98
- 238000011282 treatment Methods 0.000 claims description 89
- 210000000577 adipose tissue Anatomy 0.000 claims description 81
- 210000002460 smooth muscle Anatomy 0.000 claims description 67
- 239000011886 peripheral blood Substances 0.000 claims description 57
- 210000005259 peripheral blood Anatomy 0.000 claims description 56
- 238000002513 implantation Methods 0.000 claims description 53
- 238000000151 deposition Methods 0.000 claims description 46
- 210000003815 abdominal wall Anatomy 0.000 claims description 43
- 238000001356 surgical procedure Methods 0.000 claims description 42
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 41
- 210000004877 mucosa Anatomy 0.000 claims description 34
- 230000002950 deficient Effects 0.000 claims description 22
- 210000000981 epithelium Anatomy 0.000 claims description 17
- 230000003872 anastomosis Effects 0.000 claims description 10
- 230000004069 differentiation Effects 0.000 claims description 10
- 239000002771 cell marker Substances 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 7
- 230000005012 migration Effects 0.000 claims description 7
- 238000013508 migration Methods 0.000 claims description 7
- 230000001720 vestibular Effects 0.000 claims description 7
- 230000002500 effect on skin Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 210000002919 epithelial cell Anatomy 0.000 claims description 4
- 229920000249 biocompatible polymer Polymers 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 description 357
- 238000012360 testing method Methods 0.000 description 344
- 210000003932 urinary bladder Anatomy 0.000 description 297
- 230000002485 urinary effect Effects 0.000 description 124
- 210000001635 urinary tract Anatomy 0.000 description 91
- 210000004369 blood Anatomy 0.000 description 84
- 239000008280 blood Substances 0.000 description 84
- 230000008929 regeneration Effects 0.000 description 65
- 238000011069 regeneration method Methods 0.000 description 65
- 239000000463 material Substances 0.000 description 64
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 60
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 60
- 210000002837 heart atrium Anatomy 0.000 description 56
- 108090000623 proteins and genes Proteins 0.000 description 53
- 210000003491 skin Anatomy 0.000 description 53
- 239000000523 sample Substances 0.000 description 45
- 210000004303 peritoneum Anatomy 0.000 description 44
- 238000001574 biopsy Methods 0.000 description 40
- 230000003187 abdominal effect Effects 0.000 description 39
- 230000015572 biosynthetic process Effects 0.000 description 38
- 102000004169 proteins and genes Human genes 0.000 description 35
- 238000011887 Necropsy Methods 0.000 description 34
- 210000003205 muscle Anatomy 0.000 description 34
- 230000008021 deposition Effects 0.000 description 32
- 210000003734 kidney Anatomy 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 31
- 108010035532 Collagen Proteins 0.000 description 30
- 102000008186 Collagen Human genes 0.000 description 30
- 229920001436 collagen Polymers 0.000 description 30
- 238000012258 culturing Methods 0.000 description 27
- 239000002609 medium Substances 0.000 description 27
- 108010081823 Myocardin Proteins 0.000 description 25
- 102100030217 Myocardin Human genes 0.000 description 25
- 230000008828 contractile function Effects 0.000 description 25
- 239000003550 marker Substances 0.000 description 25
- 229920000954 Polyglycolide Polymers 0.000 description 24
- 230000001965 increasing effect Effects 0.000 description 24
- 239000011148 porous material Substances 0.000 description 24
- 230000008569 process Effects 0.000 description 24
- 210000000683 abdominal cavity Anatomy 0.000 description 23
- 230000006870 function Effects 0.000 description 23
- 238000010899 nucleation Methods 0.000 description 23
- 210000003741 urothelium Anatomy 0.000 description 23
- 230000003890 fistula Effects 0.000 description 22
- 239000004633 polyglycolic acid Substances 0.000 description 22
- 239000000306 component Substances 0.000 description 21
- 230000008602 contraction Effects 0.000 description 21
- 238000011161 development Methods 0.000 description 21
- 230000018109 developmental process Effects 0.000 description 21
- 238000011156 evaluation Methods 0.000 description 21
- 230000008439 repair process Effects 0.000 description 21
- 206010016717 Fistula Diseases 0.000 description 20
- 238000002574 cystoscopy Methods 0.000 description 20
- 206010061218 Inflammation Diseases 0.000 description 19
- 241001673669 Porcine circovirus 2 Species 0.000 description 19
- 230000034994 death Effects 0.000 description 19
- 231100000517 death Toxicity 0.000 description 19
- 230000004054 inflammatory process Effects 0.000 description 19
- 239000010410 layer Substances 0.000 description 19
- 229920005615 natural polymer Polymers 0.000 description 19
- 230000001172 regenerating effect Effects 0.000 description 19
- 230000017423 tissue regeneration Effects 0.000 description 19
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 18
- 102000004127 Cytokines Human genes 0.000 description 18
- 108090000695 Cytokines Proteins 0.000 description 18
- 239000011575 calcium Substances 0.000 description 18
- 229910052791 calcium Inorganic materials 0.000 description 18
- 239000003102 growth factor Substances 0.000 description 18
- 210000004072 lung Anatomy 0.000 description 18
- 229920001184 polypeptide Polymers 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 229920001059 synthetic polymer Polymers 0.000 description 18
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 17
- 239000011248 coating agent Substances 0.000 description 17
- 238000000576 coating method Methods 0.000 description 17
- 230000035876 healing Effects 0.000 description 17
- 210000000244 kidney pelvis Anatomy 0.000 description 17
- 210000001015 abdomen Anatomy 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 16
- 238000010171 animal model Methods 0.000 description 16
- 239000012091 fetal bovine serum Substances 0.000 description 16
- 230000012010 growth Effects 0.000 description 16
- 230000002980 postoperative effect Effects 0.000 description 16
- 238000004393 prognosis Methods 0.000 description 16
- 210000000130 stem cell Anatomy 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 15
- 230000003902 lesion Effects 0.000 description 15
- 230000004083 survival effect Effects 0.000 description 15
- 238000002604 ultrasonography Methods 0.000 description 15
- 230000002792 vascular Effects 0.000 description 15
- 241000282887 Suidae Species 0.000 description 14
- 206010046543 Urinary incontinence Diseases 0.000 description 14
- 229920001577 copolymer Polymers 0.000 description 14
- 230000001419 dependent effect Effects 0.000 description 14
- 210000002540 macrophage Anatomy 0.000 description 14
- 238000000926 separation method Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 13
- 102100031013 Transgelin Human genes 0.000 description 13
- 210000001185 bone marrow Anatomy 0.000 description 13
- 108010086826 calponin Proteins 0.000 description 13
- 102000006783 calponin Human genes 0.000 description 13
- 238000004113 cell culture Methods 0.000 description 13
- 210000004748 cultured cell Anatomy 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 239000000835 fiber Substances 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 230000009385 viral infection Effects 0.000 description 13
- 102000029816 Collagenase Human genes 0.000 description 12
- 108060005980 Collagenase Proteins 0.000 description 12
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 12
- 208000036142 Viral infection Diseases 0.000 description 12
- 229960002424 collagenase Drugs 0.000 description 12
- 238000003384 imaging method Methods 0.000 description 12
- 238000002955 isolation Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 230000036961 partial effect Effects 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 206010020524 Hydronephrosis Diseases 0.000 description 11
- 238000011888 autopsy Methods 0.000 description 11
- 210000002808 connective tissue Anatomy 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 210000002950 fibroblast Anatomy 0.000 description 11
- 210000001165 lymph node Anatomy 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 230000007704 transition Effects 0.000 description 11
- 210000003708 urethra Anatomy 0.000 description 11
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 10
- 102000007469 Actins Human genes 0.000 description 10
- 108010085238 Actins Proteins 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- 239000006143 cell culture medium Substances 0.000 description 10
- 230000001413 cellular effect Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 10
- 238000007726 management method Methods 0.000 description 10
- 210000005087 mononuclear cell Anatomy 0.000 description 10
- -1 polytetrafluoroethylene Polymers 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 101000817629 Homo sapiens Dymeclin Proteins 0.000 description 9
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 9
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 9
- 210000001789 adipocyte Anatomy 0.000 description 9
- 239000000560 biocompatible material Substances 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- 238000004891 communication Methods 0.000 description 9
- 239000013068 control sample Substances 0.000 description 9
- 239000003599 detergent Substances 0.000 description 9
- 210000003414 extremity Anatomy 0.000 description 9
- 210000001508 eye Anatomy 0.000 description 9
- 239000007943 implant Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 9
- 210000000663 muscle cell Anatomy 0.000 description 9
- 210000000651 myofibroblast Anatomy 0.000 description 9
- 210000000440 neutrophil Anatomy 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 8
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 8
- 108010025714 CD146 Antigen Proteins 0.000 description 8
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 description 8
- 108010090254 Growth Differentiation Factor 5 Proteins 0.000 description 8
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 description 8
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 8
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 8
- 206010021639 Incontinence Diseases 0.000 description 8
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 8
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 8
- 101150044441 PECAM1 gene Proteins 0.000 description 8
- 102100025368 Runt-related transcription factor 2 Human genes 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 241000282898 Sus scrofa Species 0.000 description 8
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 8
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 8
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 210000000936 intestine Anatomy 0.000 description 8
- 238000002357 laparoscopic surgery Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 244000309715 mini pig Species 0.000 description 8
- 238000012544 monitoring process Methods 0.000 description 8
- 210000004400 mucous membrane Anatomy 0.000 description 8
- 210000005170 neoplastic cell Anatomy 0.000 description 8
- 239000013610 patient sample Substances 0.000 description 8
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 210000005070 sphincter Anatomy 0.000 description 8
- 210000004876 tela submucosa Anatomy 0.000 description 8
- 238000002562 urinalysis Methods 0.000 description 8
- 108010047303 von Willebrand Factor Proteins 0.000 description 8
- 102100036537 von Willebrand factor Human genes 0.000 description 8
- 229960001134 von willebrand factor Drugs 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 102100032912 CD44 antigen Human genes 0.000 description 7
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 7
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 7
- 102100039065 Interleukin-1 beta Human genes 0.000 description 7
- 102000004264 Osteopontin Human genes 0.000 description 7
- 108010081689 Osteopontin Proteins 0.000 description 7
- 206010037596 Pyelonephritis Diseases 0.000 description 7
- 206010042674 Swelling Diseases 0.000 description 7
- 210000003484 anatomy Anatomy 0.000 description 7
- 239000012620 biological material Substances 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 238000012735 histological processing Methods 0.000 description 7
- 230000003284 homeostatic effect Effects 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 210000004731 jugular vein Anatomy 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 230000003442 weekly effect Effects 0.000 description 7
- 208000035143 Bacterial infection Diseases 0.000 description 6
- 206010005003 Bladder cancer Diseases 0.000 description 6
- 241000282465 Canis Species 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 6
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 6
- 208000022362 bacterial infectious disease Diseases 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- 210000005068 bladder tissue Anatomy 0.000 description 6
- 238000002659 cell therapy Methods 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 238000009799 cystectomy Methods 0.000 description 6
- 230000001086 cytosolic effect Effects 0.000 description 6
- 238000001804 debridement Methods 0.000 description 6
- 230000007547 defect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 6
- 210000003195 fascia Anatomy 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 238000002594 fluoroscopy Methods 0.000 description 6
- 210000003128 head Anatomy 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000023185 monocyte chemotactic protein-1 production Effects 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 201000005112 urinary bladder cancer Diseases 0.000 description 6
- 201000002327 urinary tract obstruction Diseases 0.000 description 6
- 210000005167 vascular cell Anatomy 0.000 description 6
- 210000001835 viscera Anatomy 0.000 description 6
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 238000010240 RT-PCR analysis Methods 0.000 description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000006065 biodegradation reaction Methods 0.000 description 5
- 238000005266 casting Methods 0.000 description 5
- 230000024245 cell differentiation Effects 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 230000030944 contact inhibition Effects 0.000 description 5
- 230000001351 cycling effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000002489 hematologic effect Effects 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 210000000713 mesentery Anatomy 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000000877 morphologic effect Effects 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 230000009772 tissue formation Effects 0.000 description 5
- 210000002417 xiphoid bone Anatomy 0.000 description 5
- 206010000050 Abdominal adhesions Diseases 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- 102100027951 Brain and acute leukemia cytoplasmic protein Human genes 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 102100036912 Desmin Human genes 0.000 description 4
- 108010044052 Desmin Proteins 0.000 description 4
- 206010013554 Diverticulum Diseases 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 206010015548 Euthanasia Diseases 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 206010018364 Glomerulonephritis Diseases 0.000 description 4
- 101000697853 Homo sapiens Brain and acute leukemia cytoplasmic protein Proteins 0.000 description 4
- 102000011782 Keratins Human genes 0.000 description 4
- 108010076876 Keratins Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102000003505 Myosin Human genes 0.000 description 4
- 108060008487 Myosin Proteins 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 239000004792 Prolene Substances 0.000 description 4
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 4
- 206010047115 Vasculitis Diseases 0.000 description 4
- 239000002251 absorbable suture material Substances 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000002146 bilateral effect Effects 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000021164 cell adhesion Effects 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 210000005045 desmin Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000001839 endoscopy Methods 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 208000030533 eye disease Diseases 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000007489 histopathology method Methods 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000001788 irregular Effects 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 210000000565 lesser omentum Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 229920000747 poly(lactic acid) Polymers 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 208000023504 respiratory system disease Diseases 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 4
- 238000009966 trimming Methods 0.000 description 4
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical class [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 4
- 210000001113 umbilicus Anatomy 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 108030001720 Bontoxilysin Proteins 0.000 description 3
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 3
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 102000002585 Contractile Proteins Human genes 0.000 description 3
- 108010068426 Contractile Proteins Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 102000006395 Globulins Human genes 0.000 description 3
- 108010044091 Globulins Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 206010020853 Hypertonic bladder Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 3
- 206010038540 Renal tubular necrosis Diseases 0.000 description 3
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003044 adaptive effect Effects 0.000 description 3
- 210000004504 adult stem cell Anatomy 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 239000012670 alkaline solution Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 229940053031 botulinum toxin Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000000748 compression moulding Methods 0.000 description 3
- 210000000555 contractile cell Anatomy 0.000 description 3
- 238000005138 cryopreservation Methods 0.000 description 3
- 230000000254 damaging effect Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 230000001497 fibrovascular Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000007443 liposuction Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 3
- 210000000107 myocyte Anatomy 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 208000020629 overactive bladder Diseases 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000011472 radical prostatectomy Methods 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000007447 staining method Methods 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 210000004003 subcutaneous fat Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000008093 supporting effect Effects 0.000 description 3
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000034309 Bacterial disease carrier Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 101710092112 Calponin-1 Proteins 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102100037241 Endoglin Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 2
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 208000008081 Intestinal Fistula Diseases 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- 208000035965 Postoperative Complications Diseases 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 206010072170 Skin wound Diseases 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 2
- 102100030859 Tissue factor Human genes 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 241001227561 Valgus Species 0.000 description 2
- 208000024248 Vascular System injury Diseases 0.000 description 2
- 208000012339 Vascular injury Diseases 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000005667 attractant Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 238000004159 blood analysis Methods 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 210000001736 capillary Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000031902 chemoattractant activity Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 239000000512 collagen gel Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000003436 cytoskeletal effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000006862 enzymatic digestion Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 2
- 238000004868 gas analysis Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 239000003147 molecular marker Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 210000004197 pelvis Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000002745 poly(ortho ester) Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000004451 qualitative analysis Methods 0.000 description 2
- 238000009801 radical cystectomy Methods 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 210000002163 scaffold cell Anatomy 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000000807 solvent casting Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 239000003106 tissue adhesive Substances 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 210000004926 tubular epithelial cell Anatomy 0.000 description 2
- 206010046494 urge incontinence Diseases 0.000 description 2
- OBHRVMZSZIDDEK-UHFFFAOYSA-N urobilinogen Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(CC3C(=C(CC)C(=O)N3)C)N2)CCC(O)=O)N1 OBHRVMZSZIDDEK-UHFFFAOYSA-N 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 238000009941 weaving Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 2
- NGZXDRGWBULKFA-NSOVKSMOSA-N (+)-Bebeerine Chemical compound C([C@@H]1N(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 NGZXDRGWBULKFA-NSOVKSMOSA-N 0.000 description 1
- HEGSGKPQLMEBJL-RQICVUQASA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-6-octoxyoxane-3,4,5-triol Chemical compound CCCCCCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RQICVUQASA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- WSSSPWUEQFSQQG-UHFFFAOYSA-N 4-methyl-1-pentene Chemical compound CC(C)CC=C WSSSPWUEQFSQQG-UHFFFAOYSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 102100031786 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 238000010953 Ames test Methods 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101100243025 Arabidopsis thaliana PCO2 gene Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010061698 Bladder injury Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 102000004497 CCR2 Receptors Human genes 0.000 description 1
- 108010017312 CCR2 Receptors Proteins 0.000 description 1
- 102100024210 CD166 antigen Human genes 0.000 description 1
- 101150093802 CXCL1 gene Proteins 0.000 description 1
- 102100029761 Cadherin-5 Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920013683 Celanese Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 206010013530 Diverticula Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 206010014172 Ectopic ureter Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 1
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- DHUZAAUGHUHIDS-ONEGZZNKSA-N Isomyristicin Chemical compound COC1=CC(\C=C\C)=CC2=C1OCO2 DHUZAAUGHUHIDS-ONEGZZNKSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 1
- 208000010495 Meningocele Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102100027439 Nucleobindin-1 Human genes 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010034238 Pelvic adhesions Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004696 Poly ether ether ketone Substances 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004962 Polyamide-imide Substances 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 239000004697 Polyetherimide Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004734 Polyphenylene sulfide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038481 Renal necrosis Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 101710102802 Runt-related transcription factor 2 Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 229920004929 Triton X-114 Polymers 0.000 description 1
- 229920004896 Triton X-405 Polymers 0.000 description 1
- 229920004898 Triton X-705 Polymers 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- 208000028484 Urethral disease Diseases 0.000 description 1
- 206010046479 Urethral valves Diseases 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000003433 aortic smooth muscle cell Anatomy 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000003443 bladder cell Anatomy 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 108010018828 cadherin 5 Proteins 0.000 description 1
- 239000003715 calcium chelating agent Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000012534 cell culture medium component Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229940127243 cholinergic drug Drugs 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 208000037516 chromosome inversion disease Diseases 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 210000003104 cytoplasmic structure Anatomy 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-M deoxycholate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-M 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000009547 development abnormality Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- CURUTKGFNZGFSE-UHFFFAOYSA-N dicyclomine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 description 1
- 229960002777 dicycloverine Drugs 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 210000005119 human aortic smooth muscle cell Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 201000006318 hyperopia Diseases 0.000 description 1
- 230000004305 hyperopia Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 206010020745 hyperreflexia Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000036724 intravesical pressure Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 238000012977 invasive surgical procedure Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003130 muscle precursor cell Anatomy 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000003365 myofibril Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 230000033667 organ regeneration Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000000505 parietal peritoneum Anatomy 0.000 description 1
- 210000003049 pelvic bone Anatomy 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001643 poly(ether ketone) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920002312 polyamide-imide Polymers 0.000 description 1
- 229920002577 polybenzoxazole Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920002530 polyetherether ketone Polymers 0.000 description 1
- 229920001601 polyetherimide Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- ODGAOXROABLFNM-UHFFFAOYSA-N polynoxylin Chemical compound O=C.NC(N)=O ODGAOXROABLFNM-UHFFFAOYSA-N 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920006380 polyphenylene oxide Polymers 0.000 description 1
- 229920000069 polyphenylene sulfide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000005077 polysulfide Substances 0.000 description 1
- 229920001021 polysulfide Polymers 0.000 description 1
- 150000008117 polysulfides Polymers 0.000 description 1
- 229920006295 polythiol Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 201000010041 presbyopia Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 229960005439 propantheline bromide Drugs 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 210000003689 pubic bone Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011470 radical surgery Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012779 reinforcing material Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000000518 sarcolemma Anatomy 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 230000037370 skin discoloration Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000050 smooth muscle relaxant Substances 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000003356 suture material Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000003202 urodynamic effect Effects 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11124208P | 2008-11-04 | 2008-11-04 | |
| US61/111,242 | 2008-11-04 | ||
| US11354208P | 2008-11-11 | 2008-11-11 | |
| US61/113,542 | 2008-11-11 | ||
| US11402108P | 2008-11-12 | 2008-11-12 | |
| US61/114,021 | 2008-11-12 | ||
| US11438808P | 2008-11-13 | 2008-11-13 | |
| US11438208P | 2008-11-13 | 2008-11-13 | |
| US61/114,388 | 2008-11-13 | ||
| US61/114,382 | 2008-11-13 | ||
| US20155008P | 2008-12-10 | 2008-12-10 | |
| US20155408P | 2008-12-10 | 2008-12-10 | |
| US20155508P | 2008-12-10 | 2008-12-10 | |
| US61/201,550 | 2008-12-10 | ||
| US61/201,554 | 2008-12-10 | ||
| US61/201,555 | 2008-12-10 | ||
| PCT/US2009/063306 WO2010054013A2 (en) | 2008-11-04 | 2009-11-04 | Cell-scaffold constructs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014127197A Division JP6121948B2 (ja) | 2008-11-04 | 2014-06-20 | 細胞足場構造体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012510302A JP2012510302A (ja) | 2012-05-10 |
| JP2012510302A5 true JP2012510302A5 (enExample) | 2014-08-14 |
| JP6124041B2 JP6124041B2 (ja) | 2017-05-10 |
Family
ID=41600400
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011534906A Active JP6124041B2 (ja) | 2008-11-04 | 2009-11-04 | 細胞足場構造体 |
| JP2014127197A Active JP6121948B2 (ja) | 2008-11-04 | 2014-06-20 | 細胞足場構造体 |
| JP2017065065A Pending JP2017159048A (ja) | 2008-11-04 | 2017-03-29 | 細胞足場構造体 |
| JP2018200327A Pending JP2019048094A (ja) | 2008-11-04 | 2018-10-24 | 細胞足場構造体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014127197A Active JP6121948B2 (ja) | 2008-11-04 | 2014-06-20 | 細胞足場構造体 |
| JP2017065065A Pending JP2017159048A (ja) | 2008-11-04 | 2017-03-29 | 細胞足場構造体 |
| JP2018200327A Pending JP2019048094A (ja) | 2008-11-04 | 2018-10-24 | 細胞足場構造体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US8337485B2 (enExample) |
| EP (2) | EP2352529B1 (enExample) |
| JP (4) | JP6124041B2 (enExample) |
| KR (5) | KR101724639B1 (enExample) |
| CN (2) | CN102271722B (enExample) |
| AU (1) | AU2009313554B2 (enExample) |
| CA (1) | CA2742599A1 (enExample) |
| ES (1) | ES2689932T3 (enExample) |
| HK (1) | HK1205923A1 (enExample) |
| NZ (3) | NZ593208A (enExample) |
| PL (1) | PL2352529T3 (enExample) |
| PT (1) | PT2352529T (enExample) |
| WO (1) | WO2010054013A2 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020045260A1 (en) * | 2000-10-17 | 2002-04-18 | Shih-Chieh Hung | Method of isolating mesenchymal stem cells |
| US9056201B1 (en) | 2008-01-07 | 2015-06-16 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| US8608632B1 (en) | 2009-07-03 | 2013-12-17 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive extraocular delivery of radiation and/or pharmaceutics to the posterior portion of the eye |
| US10022558B1 (en) | 2008-01-07 | 2018-07-17 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| US8602959B1 (en) | 2010-05-21 | 2013-12-10 | Robert Park | Methods and devices for delivery of radiation to the posterior portion of the eye |
| CA2714985C (en) * | 2008-01-07 | 2018-05-15 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive extraocular delivery of radiation to the posterior portion of the eye |
| US9873001B2 (en) | 2008-01-07 | 2018-01-23 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| KR101724639B1 (ko) * | 2008-11-04 | 2017-04-07 | 리젠메드 (케이만) 엘티디. | 세포-지지체 구조물 |
| USD691270S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to an eye |
| USD691267S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to eye |
| USD691268S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to eye |
| USD691269S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to an eye |
| WO2011053908A1 (en) * | 2009-11-02 | 2011-05-05 | Salutaris Medical Devices, Inc. | Methods and devices for delivering appropriate minimally-invasive extraocular radiation |
| AU2011224448A1 (en) * | 2010-03-09 | 2012-09-27 | Tengion, Inc. | Cell-scaffold constructs |
| CA3025090A1 (en) * | 2010-05-03 | 2011-11-10 | Inregen | Smooth muscle cell constructs |
| KR102302069B1 (ko) | 2010-11-10 | 2021-09-14 | 인리젠 | 장기 확대를 위한 주사가능 제제 |
| DK3011936T3 (da) | 2011-01-06 | 2019-05-20 | Humacyte | Vævsmanipulerede konstrukter |
| US9993505B2 (en) | 2012-01-31 | 2018-06-12 | Wake Forest University Health Sciences | Innervation of engineered structures |
| US11311367B2 (en) | 2012-01-31 | 2022-04-26 | Wake Forest University Health Sciences | Tissue-engineered gut-sphincter complexes and methods of making the same |
| US20130317315A1 (en) * | 2012-05-22 | 2013-11-28 | Tony V. Lu | Method of age management |
| US20130317622A1 (en) * | 2012-05-25 | 2013-11-28 | Antonio Sambusseti | Surgical method for grafting an artificial implant in a bladder and/or in a urethral or ureteral segment |
| PL3567099T3 (pl) | 2012-10-24 | 2021-11-29 | Prokidney | Populacje komórek nerkowych i ich zastosowania |
| US10028857B2 (en) * | 2013-02-15 | 2018-07-24 | Convatec Technologies Inc | Methods and systems for ostomy care |
| CN103393482B (zh) * | 2013-08-14 | 2016-04-06 | 北京瑞健高科生物科技有限公司 | 一种基于组织基质材料的乳房假体支撑装置及其制备方法 |
| ITMI20131716A1 (it) | 2013-10-16 | 2015-04-17 | Antonio Sambusseti | Supporto tubolare assorbibile per patch tubolare destinato alla ricostruzione tissutale di segmenti uretrali e/o ureterali asportati |
| GB201322869D0 (en) * | 2013-12-23 | 2014-02-12 | Ucl Business Plc | Therapeutic agents and delivery with microspheres |
| US20160074186A1 (en) | 2014-09-15 | 2016-03-17 | Covidien Lp | Coupling a body conduit to tissue |
| CN107073161B (zh) * | 2014-10-01 | 2020-11-03 | 3M创新有限公司 | 用于清创术的多孔装置、套件和方法 |
| CN117838375A (zh) * | 2015-03-19 | 2024-04-09 | 南洋理工大学 | 支架组件和制备支架组件的方法 |
| US20170051016A1 (en) | 2015-08-17 | 2017-02-23 | Northwestern University | Anti-inflammatory nanofibers |
| WO2017056866A1 (ja) * | 2015-09-29 | 2017-04-06 | 株式会社カネカ | 生体組織作製情報生成装置、生体組織作製システム、医療費演算システム |
| US20190015190A1 (en) | 2015-12-30 | 2019-01-17 | Wake Forest University Health Sciences | Tissue-engineered gut-sphincter complexes and methods of making the same |
| RU2633309C2 (ru) * | 2016-02-25 | 2017-10-11 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Тверской государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО Тверской ГМУ Минздрава России) | Комбинированный хирургический дренаж |
| USD815285S1 (en) | 2016-05-11 | 2018-04-10 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| USD814638S1 (en) | 2016-05-11 | 2018-04-03 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| USD814637S1 (en) | 2016-05-11 | 2018-04-03 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| US10548977B1 (en) | 2016-05-20 | 2020-02-04 | Emery Korpas | Pain relief utilizing a combination of polymer based materials |
| US10702704B2 (en) | 2016-05-20 | 2020-07-07 | E.K. Licensing, Llc | Pain relief utilizing polymer based materials or a combination of LED bulbs, polymer based materials and a near field accelerator |
| USD808529S1 (en) | 2016-08-31 | 2018-01-23 | Salutaris Medical Devices, Inc. | Holder for a brachytherapy device |
| USD808528S1 (en) | 2016-08-31 | 2018-01-23 | Salutaris Medical Devices, Inc. | Holder for a brachytherapy device |
| EP3624729A1 (en) * | 2017-05-19 | 2020-03-25 | Mayo Foundation for Medical Education and Research | Methods and materials for treating urinary calculi |
| US11443433B2 (en) * | 2018-02-10 | 2022-09-13 | The Trustees Of The University Of Pennsylvania | Quantification and staging of body-wide tissue composition and of abnormal states on medical images via automatic anatomy recognition |
| CN113038907B (zh) | 2018-07-06 | 2024-09-03 | 库克医学技术有限责任公司 | 储存装置、装载装置、递送系统、套件、以及相关方法 |
| CN110448730A (zh) * | 2019-08-29 | 2019-11-15 | 上海白衣缘生物工程有限公司 | 一种用于鼓膜修复的生物补片及其制备方法 |
| GB2601793B (en) * | 2020-12-10 | 2025-07-23 | The Francis Crick Institute Ltd | Thymic constructs and uses thereof |
| CN113750297B (zh) * | 2021-09-03 | 2022-04-15 | 东华大学 | 一种结构和功能仿生尿道支架及其制备方法 |
| US20230132318A1 (en) * | 2021-10-25 | 2023-04-27 | Satellite Biosciences, Inc. | Methods of implanting engineered tissue constructs |
| CN114848898B (zh) * | 2022-06-23 | 2023-07-21 | 点云生物(杭州)有限公司 | 一种基于3d打印工艺制造的人工骨支架及方法 |
| WO2024044371A2 (en) * | 2022-08-26 | 2024-02-29 | The Texas A&M University System | Tubular structures, methods, and apparatuses for making and using the same |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4182339A (en) | 1978-05-17 | 1980-01-08 | Hardy Thomas G Jr | Anastomotic device and method |
| US4217664A (en) * | 1979-02-02 | 1980-08-19 | Faso Joseph M | Prosthesis and method for creating a stoma |
| US4520821A (en) | 1982-04-30 | 1985-06-04 | The Regents Of The University Of California | Growing of long-term biological tissue correction structures in vivo |
| US5863531A (en) | 1986-04-18 | 1999-01-26 | Advanced Tissue Sciences, Inc. | In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework |
| US5804178A (en) | 1986-11-20 | 1998-09-08 | Massachusetts Institute Of Technology | Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue |
| CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
| US5567612A (en) | 1986-11-20 | 1996-10-22 | Massachusetts Institute Of Technology | Genitourinary cell-matrix structure for implantation into a human and a method of making |
| WO1993007913A1 (en) | 1991-10-24 | 1993-04-29 | Children's Medical Center Corporation | Neomorphogenesis of urological structures in vivo from cell culture |
| US6283761B1 (en) | 1992-09-08 | 2001-09-04 | Raymond Anthony Joao | Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information |
| US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
| US5399352A (en) * | 1993-04-14 | 1995-03-21 | Emory University | Device for local drug delivery and methods for using the same |
| US6039749A (en) * | 1994-02-10 | 2000-03-21 | Endovascular Systems, Inc. | Method and apparatus for deploying non-circular stents and graftstent complexes |
| US20020055786A1 (en) * | 1994-08-16 | 2002-05-09 | Anthony Atala | Reconstruction of urological structures with polymeric matrices |
| US5654273A (en) | 1994-09-22 | 1997-08-05 | Children's Medical Center Corporation | Synducin mediated modulation of tissue repair |
| US5618718A (en) | 1994-12-30 | 1997-04-08 | Universite Laval | Production of a contractile smooth muscle |
| US5586438A (en) | 1995-03-27 | 1996-12-24 | Organ, Inc. | Portable device for preserving organs by static storage or perfusion |
| DE69622548T2 (de) | 1995-04-07 | 2003-09-18 | Methodist Health Group, Inc. | Gewebetransplantat zur blasenrekonstruktion |
| US5855610A (en) | 1995-05-19 | 1999-01-05 | Children's Medical Center Corporation | Engineering of strong, pliable tissues |
| US6090618A (en) * | 1996-10-07 | 2000-07-18 | Arch Development Corporation | DNA constructs and viral vectors comprising a smooth muscle promoter |
| US5714359A (en) | 1995-10-12 | 1998-02-03 | The University Of Akron | Apparatus and method for electrostatic endothelial cell seeding in a vascular prosthesis |
| US6171344B1 (en) | 1996-08-16 | 2001-01-09 | Children's Medical Center Corporation | Bladder submucosa seeded with cells for tissue reconstruction |
| US5902336A (en) * | 1996-10-15 | 1999-05-11 | Mirimedical, Inc. | Implantable device and method for removing fluids from the blood of a patient method for implanting such a device and method for treating a patient experiencing renal failure |
| AU743779B2 (en) * | 1996-12-10 | 2002-02-07 | Cook Biotech, Inc. | Tubular grafts from purified submucosa |
| FR2759575B1 (fr) | 1997-02-14 | 1999-04-30 | Assist Publ Hopitaux De Paris | Implant artificiel destine au remplacement de l'appareil excreteur urinaire chez l'etre humain |
| CA2306346C (en) | 1997-07-03 | 2010-09-14 | Massachusetts Institute Of Technology | Tissue-engineered tubular construct having circumferentially oriented smooth muscle cells |
| US6142272A (en) * | 1997-08-26 | 2000-11-07 | Luk Getriebe-Systeme Gmbh | Hydrodynamic torque converter |
| CA2307567C (en) * | 1997-10-31 | 2009-01-20 | Children's Medical Center Corporation | Polymer matrix/cell construct for bladder reconstruction |
| AU1588099A (en) | 1997-11-17 | 1999-06-07 | Beth Israel Deaconess Medical Center | Hybrid tissues for tissue engineering |
| US6371992B1 (en) * | 1997-12-19 | 2002-04-16 | The Regents Of The University Of California | Acellular matrix grafts: preparation and use |
| US20030082152A1 (en) | 1999-03-10 | 2003-05-01 | Hedrick Marc H. | Adipose-derived stem cells and lattices |
| DE19912472B4 (de) | 1999-03-18 | 2011-03-17 | Wassermann, Helmut, Prof. | Künstliches Harnableitungssystem |
| US7131996B2 (en) | 1999-03-18 | 2006-11-07 | Helmut Wasserman | Artificial urinary diversion device |
| US6709465B2 (en) * | 1999-03-18 | 2004-03-23 | Fossa Medical, Inc. | Radially expanding ureteral device |
| US6503273B1 (en) | 1999-11-22 | 2003-01-07 | Cyograft Tissue Engineering, Inc. | Tissue engineered blood vessels and methods and apparatus for their manufacture |
| US6432712B1 (en) | 1999-11-22 | 2002-08-13 | Bioscience Consultants, Llc | Transplantable recellularized and reendothelialized vascular tissue graft |
| US6428802B1 (en) | 1999-12-29 | 2002-08-06 | Children's Medical Center Corp. | Preparing artificial organs by forming polylayers of different cell populations on a substrate |
| US6376244B1 (en) | 1999-12-29 | 2002-04-23 | Children's Medical Center Corporation | Methods and compositions for organ decellularization |
| US6866686B2 (en) * | 2000-01-28 | 2005-03-15 | Cryolife, Inc. | Tissue graft |
| AT411328B (de) * | 2000-07-12 | 2003-12-29 | Universitaetsklinikum Freiburg | Röhrensystem zur rekonstruktion einer harnröhre |
| KR20020094074A (ko) * | 2001-06-07 | 2002-12-18 | (주)에이치비메디컬스 | 체내 이식관 |
| NZ536563A (en) * | 2002-05-02 | 2008-03-28 | Purdue Research Foundation | Vascularization enhanced graft constructs |
| US7299805B2 (en) * | 2002-06-07 | 2007-11-27 | Marctec, Llc | Scaffold and method for implanting cells |
| US20040029266A1 (en) | 2002-08-09 | 2004-02-12 | Emilio Barbera-Guillem | Cell and tissue culture device |
| CN1194653C (zh) * | 2002-12-30 | 2005-03-30 | 中国中医研究院西苑医院 | 具有防治再狭窄药物涂层的体内腔管内支架及其制造方法 |
| US7182745B2 (en) * | 2003-03-25 | 2007-02-27 | Boston Scientific Scimed, Inc. | Retaining stent |
| GB0402103D0 (en) * | 2004-02-02 | 2004-03-03 | Hengelmolen Rudy | Tubular graft |
| AU2005219660B2 (en) * | 2004-03-09 | 2009-07-16 | Absorber Ab | Endothelial progenitor cells and methods of use thereof |
| CN101141933B (zh) * | 2004-03-10 | 2015-07-29 | 祥丰医疗有限公司 | 内皮配体结合涂覆的医疗装置 |
| US8425539B2 (en) * | 2004-04-12 | 2013-04-23 | Xlumena, Inc. | Luminal structure anchoring devices and methods |
| US9801527B2 (en) * | 2004-04-19 | 2017-10-31 | Gearbox, Llc | Lumen-traveling biological interface device |
| US7935096B2 (en) * | 2004-09-06 | 2011-05-03 | Ostomycure As | Percutaneous implant |
| US20060199265A1 (en) * | 2005-03-02 | 2006-09-07 | Wolf Michael F | Seeding implantable medical devices with cells |
| US7531503B2 (en) * | 2005-03-11 | 2009-05-12 | Wake Forest University Health Sciences | Cell scaffold matrices with incorporated therapeutic agents |
| US20080109058A1 (en) * | 2005-06-01 | 2008-05-08 | Cook Incorporated | Intraoperative Anastomosis Method |
| WO2007001992A2 (en) * | 2005-06-21 | 2007-01-04 | Regents Of The University Of Minnesota | Ureteral stent with axial and radial variability |
| US7531355B2 (en) | 2005-07-29 | 2009-05-12 | The Regents Of The University Of California | Methods and compositions for smooth muscle reconstruction |
| FR2890977A1 (fr) * | 2005-09-19 | 2007-03-23 | Assist Publ Hopitaux De Paris | Procede d'obtention de cellules musculaires lisses humaines et leurs applications |
| ITMI20051854A1 (it) * | 2005-10-03 | 2007-04-04 | Sambusseti Antonio | Patch per la sostituzione di una porzione di parete vescicale a seguito di vescitectomia parziale |
| JP4644786B2 (ja) * | 2005-10-18 | 2011-03-02 | 国立大学法人 東京医科歯科大学 | マイクロビーズの製造方法 |
| WO2007095192A2 (en) | 2006-02-10 | 2007-08-23 | Tengion Inc. | Bioreactor for organ reconstruction and augmentation |
| CA2641733C (en) * | 2006-02-10 | 2015-03-31 | Tengion, Inc. | Scaffolds for organ reconstruction and augmentation |
| US20080081323A1 (en) * | 2006-09-29 | 2008-04-03 | Daniel Keeley | Regenerative Medicine Devices and Melt-Blown Methods of Manufacture |
| EP2180906B1 (fr) * | 2007-08-31 | 2014-12-24 | Synolyne Pharma | Prothese destinee a promouvoir la reconstruction in vivo d'un organe creux ou d'une partie d'organe creux |
| US8992409B2 (en) * | 2007-10-11 | 2015-03-31 | Peter Forsell | Method for controlling flow in a bodily organ |
| CN101147810B (zh) * | 2007-11-01 | 2010-05-19 | 南昌大学第一附属医院 | 细胞-生物可降解材料复合物及其制备方法和应用 |
| EP2210248B1 (en) | 2007-11-13 | 2016-04-20 | Cook Medical Technologies LLC | Intraluminal bypass prosthesis |
| US20090254039A1 (en) * | 2007-12-21 | 2009-10-08 | O'brien Nicole Sams | Designer accessory for use with an intracorporeal medical device |
| KR101724639B1 (ko) * | 2008-11-04 | 2017-04-07 | 리젠메드 (케이만) 엘티디. | 세포-지지체 구조물 |
| US8192500B2 (en) * | 2008-12-12 | 2012-06-05 | Boston Scientific Scimed, Inc. | Ureteral stent |
| WO2010087769A1 (en) * | 2009-01-29 | 2010-08-05 | Milux Holding S.A | Implant comprising an expandable section |
| US8900116B2 (en) * | 2009-07-14 | 2014-12-02 | Stimatix Gi Ltd. | Inflatable stomal implant |
| CA3025090A1 (en) * | 2010-05-03 | 2011-11-10 | Inregen | Smooth muscle cell constructs |
| WO2012016575A1 (en) * | 2010-08-03 | 2012-02-09 | King Saud University | Stoma coat |
| US20120095483A1 (en) * | 2010-10-19 | 2012-04-19 | Allergan, Inc. | Anchored non-piercing duodenal sleeve and delivery systems |
-
2009
- 2009-11-04 KR KR1020117012781A patent/KR101724639B1/ko not_active Expired - Fee Related
- 2009-11-04 KR KR1020197016239A patent/KR20190067267A/ko not_active Ceased
- 2009-11-04 NZ NZ59320809A patent/NZ593208A/xx not_active IP Right Cessation
- 2009-11-04 EP EP09753285.7A patent/EP2352529B1/en active Active
- 2009-11-04 ES ES09753285T patent/ES2689932T3/es active Active
- 2009-11-04 CN CN200980153634.8A patent/CN102271722B/zh not_active Expired - Fee Related
- 2009-11-04 WO PCT/US2009/063306 patent/WO2010054013A2/en not_active Ceased
- 2009-11-04 KR KR1020187031781A patent/KR20180122484A/ko not_active Ceased
- 2009-11-04 NZ NZ60429609A patent/NZ604296A/en not_active IP Right Cessation
- 2009-11-04 NZ NZ626419A patent/NZ626419A/en not_active IP Right Cessation
- 2009-11-04 PT PT09753285T patent/PT2352529T/pt unknown
- 2009-11-04 PL PL09753285T patent/PL2352529T3/pl unknown
- 2009-11-04 CN CN201410270167.XA patent/CN104274256A/zh active Pending
- 2009-11-04 EP EP18175242.9A patent/EP3461507A1/en not_active Withdrawn
- 2009-11-04 JP JP2011534906A patent/JP6124041B2/ja active Active
- 2009-11-04 CA CA2742599A patent/CA2742599A1/en not_active Abandoned
- 2009-11-04 KR KR1020187008826A patent/KR20180034707A/ko not_active Ceased
- 2009-11-04 KR KR1020177009069A patent/KR20170041279A/ko not_active Ceased
- 2009-11-04 US US12/612,606 patent/US8337485B2/en not_active Expired - Fee Related
- 2009-11-04 AU AU2009313554A patent/AU2009313554B2/en not_active Ceased
-
2012
- 2012-11-20 US US13/682,614 patent/US9271824B2/en not_active Expired - Fee Related
-
2014
- 2014-06-20 JP JP2014127197A patent/JP6121948B2/ja active Active
-
2015
- 2015-07-14 HK HK15106716.3A patent/HK1205923A1/xx unknown
-
2017
- 2017-03-29 JP JP2017065065A patent/JP2017159048A/ja active Pending
- 2017-05-18 US US15/599,137 patent/US20180071074A1/en not_active Abandoned
-
2018
- 2018-10-24 JP JP2018200327A patent/JP2019048094A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6121948B2 (ja) | 細胞足場構造体 | |
| JP2012510302A5 (enExample) | ||
| CN103025361B (zh) | 平滑肌细胞结构 | |
| KR20130005285A (ko) | 세포 골격 구조물 | |
| Rothberg et al. | History and development of regenerative medicine and tissue engineering in urology | |
| CA3037457A1 (en) | Cell-scaffold constructs | |
| AU2019202548A1 (en) | Cell-scaffold constructs | |
| HK1159529A (en) | Cell-scaffold constructs | |
| HK1159529B (en) | Cell-scaffold constructs | |
| HK1232810A1 (en) | Smooth muscle cell constructs |